A Phase II Study of LBH589B in Adult Patients with Refractory Cutaneous T-Cell Lymphoma and Prior HDAC Inhibitor Therapy.

Trial Profile

A Phase II Study of LBH589B in Adult Patients with Refractory Cutaneous T-Cell Lymphoma and Prior HDAC Inhibitor Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Mar 2009 New source identified and integrated (University of Washington Health Sciences record 6588).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top